Eurobio Scientific SA (ALERS) - Total Assets
Based on the latest financial reports, Eurobio Scientific SA (ALERS) holds total assets worth €259.11 Million EUR (≈ $302.92 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eurobio Scientific SA - Total Assets Trend (2007–2024)
This chart illustrates how Eurobio Scientific SA's total assets have evolved over time, based on quarterly financial data. Also see Eurobio Scientific SA (ALERS) market capitalisation for the company's overall valuation and market capitalisation.
Eurobio Scientific SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Eurobio Scientific SA's total assets of €259.11 Million consist of 34.8% current assets and 65.2% non-current assets. Review Eurobio Scientific SA debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €23.07 Million | 8.5% |
| Accounts Receivable | €33.16 Million | 12.9% |
| Inventory | €26.92 Million | 10.5% |
| Property, Plant & Equipment | €12.77 Million | 5.0% |
| Intangible Assets | €34.62 Million | 13.5% |
| Goodwill | €118.90 Million | 46.2% |
Asset Composition Trend (2007–2024)
This chart illustrates how Eurobio Scientific SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ALERS stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eurobio Scientific SA's current assets represent 34.8% of total assets in 2024, a decrease from 90.2% in 2007.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, down from 17.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 5.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 46.2% of total assets.
Eurobio Scientific SA Competitors by Total Assets
Key competitors of Eurobio Scientific SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €408.98 Million |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
DRTECH Corporation
KQ:214680
|
Korea | ₩235.84 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
Eurobio Scientific SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 2.69 | 1.87 |
| Quick Ratio | 1.86 | 2.26 | 1.55 |
| Cash Ratio | 0.74 | 1.59 | 0.42 |
| Working Capital | €60.76 Million | €92.12 Million | €33.99 Million |
Eurobio Scientific SA - Advanced Valuation Insights
This section examines the relationship between Eurobio Scientific SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.92 |
| Asset Growth Rate (YoY) | -18.7% |
| Total Assets | €257.17 Million |
| Market Capitalization | $236.10 Million USD |
Valuation Analysis
Near Book Valuation: The market values Eurobio Scientific SA's assets close to their book value (0.92x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Eurobio Scientific SA's assets decreased by 18.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eurobio Scientific SA (2007–2024)
The table below shows the annual total assets of Eurobio Scientific SA from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €257.17 Million ≈ $300.66 Million |
-18.70% |
| 2023-12-31 | €316.33 Million ≈ $369.82 Million |
-4.26% |
| 2022-12-31 | €330.42 Million ≈ $386.29 Million |
+57.92% |
| 2021-12-31 | €209.22 Million ≈ $244.61 Million |
+21.43% |
| 2020-12-31 | €172.30 Million ≈ $201.43 Million |
+112.70% |
| 2019-12-31 | €81.01 Million ≈ $94.70 Million |
+15.89% |
| 2018-12-31 | €69.90 Million ≈ $81.72 Million |
-2.34% |
| 2017-12-31 | €71.57 Million ≈ $83.68 Million |
+124.46% |
| 2016-12-31 | €31.89 Million ≈ $37.28 Million |
-10.71% |
| 2015-12-31 | €35.71 Million ≈ $41.75 Million |
-11.81% |
| 2014-12-31 | €40.50 Million ≈ $47.35 Million |
+21.20% |
| 2013-12-31 | €33.41 Million ≈ $39.06 Million |
-13.20% |
| 2012-12-31 | €38.49 Million ≈ $45.00 Million |
+118.68% |
| 2011-12-31 | €17.60 Million ≈ $20.58 Million |
-43.69% |
| 2010-12-31 | €31.26 Million ≈ $36.55 Million |
-14.47% |
| 2009-12-31 | €36.55 Million ≈ $42.73 Million |
+22.45% |
| 2008-12-31 | €29.85 Million ≈ $34.89 Million |
-20.60% |
| 2007-12-31 | €37.59 Million ≈ $43.95 Million |
-- |
About Eurobio Scientific SA
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more